Visit our country sites
- Visit our country sites
- CEVA corporate
- CEVA group web sites
A rich source of innovation for the Ceva Group.
If there is one field in which Ceva Santé Animale has demonstrated the full extent of its innovation capacities, it is that of companion animals.
Cat and dog behaviour
Through several major innovations, Ceva has opened up the possibility for vets to address behavioural disorders in cats and dogs, an area about which little was known until now and the subject of few clinical studies.
- 1996: Beginning of a new therapeutic approach: launch of FELIWAY® to treat behavioural disorders in cats
- 1997: Launch of SELGIAN® (Selegiline) to treat behavioural disorders in dogs
- 2000: Launch of D.A.P.® providing an innovative approach to the behavioural problems that are specific to the species.
Although it benefits from little media attention (compared with flea treatments, for example!), cardiology is a science in which progress is being achieved, extending the lifespan of dogs in parallel with that of their owners.
Why should we just accept the accelerated ageing of our trusty companions when the owner is treated for the same type of pathology?
It is this type of modern sociological approach to the issue that drove the CEVA Group pharmaceutical development teams to propose a range of medicines to treat heart problems in dogs, including PRILENAL® (enalapril) and, above all, PRILACTONE® (spironolactone), the world’s first veterinary application of a molecule already in use in human medicine.
Locomotion and Analgesia
With animal welfare in mind, Ceva offers a range of medicines to relieve pain in companion animals.
Thanks to injectable drugs developed by CEVA, the vet can treat pain caused by surgical operations in dogs and cats (VETERGESIC®, MELOXIDYL®).
Chronic pain is also a major problem: one of the leading causes of chronic pain is osteoarthritis, which affects dogs and cats from the age of 7 onward.
For these animals CEVA has developed special drugs recognized for their efficacy: anti-inflammatories (CARPRODYL®, DOLAGIS®, MELOXIDYL®) or chondroprotective agents (FLEXIVET®, AGILIUM+®).
But the main example of locomotor disability is lameness in horses.
This extreme case has only one genuine therapeutic solution, with the introduction on the European market in 2001 of TILDREN® (tiludronate), the first veterinary bisphosphonate, which has enabled lameness in horses to be treated effectively.
Antibiotic treatment is one of Ceva’s areas of expertise, with the company offering a very wide range of antibiotic molecules.
Alongside veterinarians, Ceva is committed to the reasoned use of antibiotics. All the antibiotics developed by Ceva are DELICAMENTS® designed to encourage compliance with good practices. The palatability of the tablets contributes to better compliance among dogs and, above all, cats, which are often difficult animals to treat. Likewise, the original dosages chosen by Ceva for its antibiotics, as well as the precision of quarter-scored pills, allows vets to prescribe antibiotic molecules with greater accuracy.
All the main families of molecules are available in this dosage form developed by the CEVA Group:
- Beta-lactam antibiotics: AMOXIVAL®, KESIUM®, THERIOS® are first-line broad-spectrum antibiotics for dogs and cats
- Lincosamides: ZODON® is a narrow-spectrum molecule that is administered only once a day.
- Fluoroquinolones: EFEX®, XEDEN® are second-line antibiotics
Other therapeutic fields
Another innovation comes in the field of reproduction: GALASTOP®, a prolactin inhibitor used to treat lactation in pseudopregnancy (“false pregnancies”) in dogs.
Mention should also be made of DIARSANYL® (Montmorillonite), an adjunct treatment for idiopathic diarrhoea in cats and dogs.
From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.